Muse Cells
A defined, marker-identified subpopulation with real clinical programmes and mixed published results.
Investigational
What it actually is
Multilineage-differentiating stress-enduring cells are a rare population identified by the surface marker SSEA-3, found within mesenchymal tissues. Two properties define them: unusual survival under cellular stress, and the ability to home to damaged tissue after intravenous infusion. Unlike pluripotent stem cells, they are reported not to form teratomas — the distinguishing safety claim of the category.
Where it comes from
Isolated as a minority fraction from bone marrow, adipose tissue or connective tissue, or from cultured MSC populations. They constitute a small percentage of the parent population, so yield and the purity of the sorting step determine whether a product is genuinely Muse-enriched or simply MSCs with a Muse label.
How it is made — and what can go wrong
Enrichment depends on SSEA-3 selection. Because the starting frequency is low, the critical questions are what proportion of the final product is actually SSEA-3 positive, and how that is verified at release. A product described as 'Muse cells' without a stated purity figure has not been characterised in the way the science defines the cell type.
Regulatory status
No approved Muse cell medicine. Clinical development has been concentrated in Japan, where trials have run in stroke, amyotrophic lateral sclerosis, spinal cord injury, acute myocardial infarction and epidermolysis bullosa. Reported outcomes across those programmes have been mixed, and the category has not yet produced a confirmatory positive phase 3.
What the evidence shows
The homing behaviour and stress tolerance are reasonably well described in preclinical work. Human efficacy remains unproven, and results from the Japanese programmes have not resolved the question.
Limits worth knowing
Rarity makes scale and consistency hard. The absence of teratoma formation is a safety advantage over pluripotent cells but says nothing about efficacy. Marketing that presents Muse cells as pluripotent overstates what the biology supports.
What this could actually be used for
A small subpopulation identified within mesenchymal cultures, described as unusually stress-tolerant and as homing to damaged tissue after intravenous delivery rather than needing to be injected into it.
The claimed advantage is targeting rather than a different repertoire: give cells systemically and let injury signals draw them to where they are needed. If that homing behaviour holds, it removes the delivery problem that limits most cell therapy — which is the entire case for treating this as a distinct cell type at all.
Acute injury with a short window 1 study registered
Homing matters most when the damaged site is hard to reach and the therapeutic window is measured in days. An intravenous infusion given in a stroke unit is operationally realistic in a way that a neurosurgical injection is not. All cell therapy research registered for this condition →
Heart and kidney injury
The same logic applied to organs where direct injection is invasive, carries its own risk, and may not be repeatable. All cell therapy research registered for this condition →
Brain injury in children and adults
Every registered study for this cell type sits in this space — traumatic brain injury, cerebral palsy, hypoxic–ischaemic encephalopathy — and all of them come from a single sponsor. The complete list is below, because at this size the list is the honest summary.
Where it stops. This is an early field by every measure available. Read the registry table below before reading any provider’s description of it: a cell type with three registered studies is not a treatment option that happens to be new, it is a research question.
What the registry actually shows for this cell type
Our own count of every study registered on ClinicalTrials.gov under this cell type, retrieved 2026-09-04. A registration is a declaration of intent, not a result — which is why the status column matters more than the total does.
| Status in the registry | Studies | Share |
|---|---|---|
| Enrolling by invitation only | 2 | 67% |
| Not yet recruiting | 1 | 33% |
| All registered studies | 3 | 100% |
Reading it: 3 studies carry no assigned trial phase, meaning they sit outside the phased development path that leads to an approved medicine. One sponsor, Healing Hope International, accounts for 3 of the 3 records, so this is closer to a single-programme field than an independently replicated one.
Every registered study for this cell type
At this size the complete list is shorter than any summary of it would be.
| Registry ID | Conditions | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07326059 | Traumatic Brain Injury, Traumatic Brain Injury (TBI) Patients, Traumat | Not yet recruiting | none assigned | Healing Hope International |
| NCT07511660 | Perimenopause, Perimenopause-Related Depression, Premature Ovarian Ins | Enrolling by invitation only | none assigned | Healing Hope International |
| NCT07521384 | Traumatic Brain Injury, Cerebral Palsy, Hypoxic Ischemic Encephalopath | Enrolling by invitation only | none assigned | Healing Hope International |
The directions above describe where the biology points and where research has been registered. They are not claims that any of it works, not evidence of benefit, and not a treatment recommendation. Counts are our own extraction from the ClinicalTrials.gov API, retrieved 2026-09-04; the queries behind them are published with the dataset so that anyone can repeat the count.
Conditions where this cell family is studied
Public registries do not carry a separate category for this sub-type. Studies using it are recorded under the broader mesenchymal stromal cell (MSC) heading, alongside bone marrow, adipose and umbilical sources. The counts below therefore describe the MSC family, which includes this preparation but is not limited to it.
From clinicaltrials.gov API v2, snapshot 2026-08-29. Dark overlay marks studies currently recruiting.
| Condition | Registered MSC studies | Recruiting now | Share |
|---|---|---|---|
| Knee osteoarthritis | 124 | 9 | 19% |
| Cirrhosis | 62 | 5 | 9% |
| Crohn disease / IBD | 52 | 6 | 8% |
| Stroke recovery | 45 | 7 | 7% |
| Spinal cord injury | 38 | 2 | 6% |
| Multiple sclerosis | 37 | 3 | 6% |
| Heart failure | 32 | 3 | 5% |
| Diabetes | 29 | 1 | 4% |
| ALS | 29 | 2 | 4% |
| Alzheimer disease | 23 | 6 | 4% |
| Lupus | 23 | 4 | 4% |
| Erectile dysfunction | 23 | 5 | 4% |
| All 26 conditions tracked | 657 | 74 | 100% |
657 registered studies across 26 conditions, of which 74 are recruiting. Knee osteoarthritis alone takes 19% of them. A provider offering this preparation for a condition near the bottom of the table is working far outside where the research sits.
One question the table cannot answer for you: ask which registered study used their preparation, from their tissue source, at their dose. A family-level count is not evidence for a specific product. The split across MSC, HSCT and exosomes is in the cell type by condition map.
What to ask before agreeing to anything
- What percentage of the administered product is SSEA-3 positive, and by which assay?
- From which tissue and by which selection method were the cells enriched?
- Which registered trial supports the proposed indication and route?
- Is this a genuinely enriched Muse product, or an MSC preparation described as one?
Sources behind the numbers on this page
- PubMed — Muse Cells
- ClinicalTrials.gov — registered studies
- EMA — advanced therapy medicinal products
- FDA — cellular and gene therapy products
Study counts above are our own extraction from ClinicalTrials.gov; the links let you reproduce them. Not medical advice, and not an assessment of whether any treatment is appropriate for you.